Public Employees Retirement System of Ohio held its stake in shares of BioSpecifics Technologies Corp (NASDAQ:BSTC) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,674 shares of the biopharmaceutical company’s stock at the end of the second quarter. Public Employees Retirement System of Ohio owned about 0.05% of BioSpecifics Technologies Corp worth $182,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the company. Renaissance Technologies LLC increased its holdings in shares of BioSpecifics Technologies Corp by 13.1% in the second quarter. Renaissance Technologies LLC now owns 398,800 shares of the biopharmaceutical company’s stock worth $19,745,000 after purchasing an additional 46,173 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of BioSpecifics Technologies Corp by 7.5% in the second quarter. Dimensional Fund Advisors LP now owns 265,676 shares of the biopharmaceutical company’s stock worth $13,154,000 after purchasing an additional 18,562 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of BioSpecifics Technologies Corp by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,454 shares of the biopharmaceutical company’s stock worth $9,924,000 after purchasing an additional 3,030 shares during the last quarter. Eagle Asset Management Inc. increased its holdings in shares of BioSpecifics Technologies Corp by 0.6% in the second quarter. Eagle Asset Management Inc. now owns 182,206 shares of the biopharmaceutical company’s stock worth $9,021,000 after purchasing an additional 1,039 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its holdings in shares of BioSpecifics Technologies Corp by 23.9% in the second quarter. Rice Hall James & Associates LLC now owns 161,671 shares of the biopharmaceutical company’s stock worth $8,004,000 after purchasing an additional 31,175 shares during the last quarter. 53.92% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BioSpecifics Technologies Corp (NASDAQ BSTC) opened at $44.12 on Friday. BioSpecifics Technologies Corp has a twelve month low of $41.95 and a twelve month high of $58.79. The stock has a market capitalization of $311.80, a PE ratio of 27.28 and a beta of 1.64.

BioSpecifics Technologies Corp (NASDAQ:BSTC) last issued its quarterly earnings data on Friday, November 10th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.01. BioSpecifics Technologies Corp had a return on equity of 19.11% and a net margin of 42.40%. The company had revenue of $6.52 million for the quarter, compared to analysts’ expectations of $6.59 million. equities analysts predict that BioSpecifics Technologies Corp will post 1.57 EPS for the current fiscal year.

Several brokerages have recently issued reports on BSTC. HC Wainwright set a $72.00 target price on BioSpecifics Technologies Corp and gave the stock a “buy” rating in a report on Thursday, August 10th. BidaskClub cut BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Zacks Investment Research raised BioSpecifics Technologies Corp from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, reduced their target price on BioSpecifics Technologies Corp from $72.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday.

WARNING: “BioSpecifics Technologies Corp (BSTC) Holdings Maintained by Public Employees Retirement System of Ohio” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/17/biospecifics-technologies-corp-bstc-holdings-maintained-by-public-employees-retirement-system-of-ohio.html.

BioSpecifics Technologies Corp Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Want to see what other hedge funds are holding BSTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioSpecifics Technologies Corp (NASDAQ:BSTC).

Institutional Ownership by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)

Receive News & Stock Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related stocks with our FREE daily email newsletter.